A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers (NAC-preHD)
Sponsor: Deakin University
A PHASE2 clinical study on Huntington Disease, this trial is actively recruiting participants. The trial is conducted by Deakin University and has accumulated 5 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Deakin University
- Monash University
- Royal Perth Hospital
- The University of Queensland
- University of Melbourne
- Western Sydney Local Health District
For direct contact, visit the study record on ClinicalTrials.gov .